Gt biopharma reports third quarter 2024 financial results

San francisco, california, nov. 14, 2024 (globe newswire) -- gt biopharma, inc. (the “company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager trike® platform, today announced third quarter 2024 financial results for the period ended september 30, 2024.

GTBP Ratings Summary

GTBP Quant Ranking